Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €148.77 EUR
Change Today +1.46 / 0.99%
Volume 10.4K
AMG On Other Exchanges
Hong Kong
Sao Paulo
As of 1:39 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMG) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - €159.75
52 Week Low
04/28/14 - €78.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AMGEN INC (AMG)

amgen inc (AMG) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company’s principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.

17,900 Employees
Last Reported Date: 02/19/15
Founded in 1980

amgen inc (AMG) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Executive Vice President of Operations
Total Annual Compensation: $1.1M
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Executive Vice President of Research & Develo...
Total Annual Compensation: $896.5K
Compensation as of Fiscal Year 2013.

amgen inc (AMG) Key Developments

Dako Announces a New Master Collaboration Agreement with Amgen Inc

Dako announced a new Master Collaboration Agreement with Amgen Inc. The expanded collaboration will allow both companies to benefit from knowledge-sharing within the field of drug-diagnostic research and development in general, and in relation to companion diagnostic products in particular. This collaboration is important in the area of personalized medicine, where targeted treatments and companion diagnostics can help identify patients for whom a particular treatment may work, leading to improved patient care and more manageable healthcare costs.

Amgen Inc. Announces Positive Data from Phase III Cholesterol Study

Amgen Inc. has announced new data from the Phase III YUKAWA-2 study evaluating Repatha, or evolocumab, an investigational cholesterol-lowering medication, in Japanese patients with high cardiovascular risk and high cholesterol. Data from the study showed subcutaneous Repatha 140 mg every two weeks or 420 mg monthly, compared to placebo, in combination with different daily doses of atorvastatin, reduced low-density lipoprotein cholesterol (LDL-C) by 67 to 76% from baseline at week 12 and at the mean of weeks 10 and 12. In the YUKAWA-2 study, the most common adverse events that occurred in greater than 2% of the Repatha group were nasopharyngitis (16.8% Repatha; 17.8% placebo), gastroenteritis (3.0% Repatha; 1.0% placebo) and pharyngitis (2.5% Repatha; 2.5%). LDL-Cholesterol Reduction Using a Monoclonal PCSK9 Antibody in Japanese Patients With Advanced Cardiovascular Risk) is a Phase III, multicenter, double-blind, randomized, placebo-controlled trial designed to evaluate the safety, tolerability and efficacy of Repatha (evolocumab) in 404 Japanese patients with high cardiovascular risk based on the Japan Atherosclerosis Society guidelines and with hyperlipidemia or mixed dyslipidemia (LDL-C greater than or equal to 100 mg/dL). Patients were randomized to one of eight treatment groups in a two-step randomization. Eligible patients were initially randomized to one of the following background therapies: atorvastatin 5 mg daily or atorvastatin 20 mg daily and entered a four-week lipid stabilization period. At completion of lipid stabilization, patients were then randomized to one of four treatment arms: Repatha 140 mg every two weeks, Repatha 420 mg monthly, subcutaneous placebo every two weeks or subcutaneous placebo monthly. The co-primary endpoints were the percentage reduction from baseline in LDL-C at week 12 and the mean percentage reduction from baseline in LDL-C at weeks 10 and 12.

Amgen Inc. - Special Call

To discuss brodalumab clinical data presented at AAD


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMG:GR €148.77 EUR +1.46

AMG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $57.65 USD +0.38
Eli Lilly & Co $73.58 USD +0.14
Gilead Sciences Inc $101.00 USD -0.075
Novo Nordisk A/S kr369.70 DKK +34.70
Teva Pharmaceutical Industries Ltd $61.98 USD -0.44
View Industry Companies

Industry Analysis


Industry Average

Valuation AMG Industry Range
Price/Earnings 24.3x
Price/Sales 6.2x
Price/Book 4.8x
Price/Cash Flow 23.9x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at